Streamlined CRISPR-Based Gene Editing For Primary Cell Engineering

Cell-based therapies are poised to revolutionize medicine, offering targeted treatments for a wide range of diseases. However, developing complex, multi-gene edited cell therapies remains a significant challenge. Traditional methods often struggle with low efficiency, cell viability, and scalability, particularly when working with primary cells.

In this poster, we present a novel approach that overcomes these limitations. By combining MaxCyte electroporation with Synthego's advanced CRISPR gene editing tools, we achieve highly efficient and reproducible gene editing in a variety of challenging primary cell types, including T cells, NK cells, keratinocytes, and macrophages. Our platform enables the precise introduction of multiple genetic modifications, opening up new possibilities for the development of next-generation cell therapies.